c-LEcta GmbH
Julia Hennicke is a skilled professional currently serving as a Biopharma Innovation Manager and previously held roles including Business Development Manager and Business Development Associate at c-LEcta GmbH since September 2019. Julia's expertise encompasses market intelligence, innovation management, and project coordination. Prior experience includes a position as a Scientist at Universität für Bodenkultur Wien from September 2015 to March 2019, where responsibilities included cell culture, IgM antibody production, and student supervision. Julia also contributed as a Visiting Research Scientist at the Institute de Biologie Structurale (IBS) in June 2018, focusing on interaction studies involving IgM and complement activation. Earlier experience involved roles at Scil Proteins GmbH, including Master Student and Student Assistant, concentrating on artificial bispecific binding proteins and recombinant expression. Julia holds a PhD in Biomolecular Technology of Proteins from the University of Natural Resources and Life Sciences, Vienna, as well as an MS and BS in Biochemistry from The Martin Luther University of Halle-Wittenberg.
This person is not in any offices
c-LEcta GmbH
c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, agenetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.